Author
Marisa Lopez‐Cruzan
- Indexed works
- 9
- Total citations
- 660
- Active years
- 5
Collaborators
Works in the record
Nature Medicine 2023
Preprint · CC-BY
Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial
Aging Cell 2021
Open access · CC-BY
17‐a‐estradiol late in life extends lifespan in aging UM‐HET3 male mice; nicotinamide riboside and three other drugs do not affect lifespan in either sex
Aging Cell 2022
Open access · CC-BY
Lifespan benefits for the combination of rapamycin plus acarbose and for captopril in genetically heterogeneous mice
GeroScience 2023
Open access · CC-BY
Astaxanthin and meclizine extend lifespan in UM-HET3 male mice; fisetin, SG1002 (hydrogen sulfide donor), dimethyl fumarate, mycophenolic acid, and 4-phenylbutyrate do not significantly affect lifespan in either sex at the doses and schedules used
Research Square 2023
Preprint · CC-BY
Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease
GeroScience 2024
Preprint · OA
Lifespan effects in male UM-HET3 mice treated with sodium thiosulfate, 16-hydroxyestriol, and late-start canagliflozin
Neurotherapeutics 2025
Open access · CC-BY
Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer’s disease
Research Square 2024
Preprint · CC-BY
Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s Disease
GeroScience 2025
Open access · CC-BY